Post-exercise Insulin Reductions in Type 1 Diabetes

Not Applicable

Completed

• Conditions: Type 1 Diabetes
• Interventions: Other: Reducing post-exercise rapid-acting insulin (insulin lispro or aspart) dose

• Registration Number: NCT01531855
• Lead Sponsor: Northumbria University

Brief Summary

The investigators hypothesise that reducing rapid-acting insulin dose after exercise will help prevent Type 1 diabetes individuals experiencing hypoglycaemia.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-02
• Study First Submitted: 2012-02-07
• Study First Submitted QC: 2012-02-10
• Study First Posted: 2012-02-13
• Primary Completion: 2012-08
• Study Completion: 2012-08
• Status Verified: 2014-08
• Last Update Submitted: 2014-08-01
• Last Update Posted: 2014-08-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 13

Inclusion Criteria

• T1DM,
• Male,
• basal-bolus regimen (insulin glargine / detemir with insulin lispro / aspart),
• HbA1c < 9.9%,
• aged 18-50.

Exclusion Criteria

• HbA1c > 10%,
• not treated with basal-bolus (insulin glargine / detemir with insulin lispro / aspart),
• aged <18 > 50.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Insulin dose	Reducing post-exercise rapid-acting insulin (insulin lispro or aspart) dose	Reducing rapid-acting insulin dose (insulin aspart or lispro) after exercise.

Primary Outcome Measures

Name	Time	Method
24 hour blood glucose area under the curve	24 hours	24 hour, post-exercise, glucose area under the curve.

Secondary Outcome Measures

Name	Time	Method
Ketogenesis	60 minutes before and 24 hours post-exercise	Blood beta-hydroxybutyrate concentrations

Trial Locations

Locations (1)

Clinical Research Facility; 🇬🇧 Newcaslte upon Tyne, Tyne and Wear, United Kingdom